PRINCETON, N.J., Feb. 06, 2018 (GLOBE NEWSWIRE) -- V ClinBio Inc., an innovative biopharmaceutical company focused on transforming existing compounds into differentiated new therapeutics, today announced that it has acquired a 49.98% equity stake in Cellix Bio, an innovative drug design and development company.Read More
Cellix Bio Publishes CLX-103 Research in International Immunopharmacology: Discovery and preclinical development of a novel prodrug conjugate of mesalamine with eicosapentaenoic acid and caprylic acid for the treatment of Inflammatory Bowel Diseases.Read More
Cellix Bio’s CLX-117 pipeline lead candidate qualifies for UConn SPARK Technology Commercialization Fund Program 2016 with the investigative supervision of Dr. Rajesh V Lalla. The award aims to help investigators from UConn-Storrs and UConn Health (UCH) move ideas into the earliest stages of commercialization and development.Read More
Cellix Bio and New Jersey Medical School, Rutgers; collaboration is focussed to screen novel anti-fungal compounds developed and patented by Cellix Bio. These novel therapies are focussed to address the drug resistance in pathogenic fungal infections.
Cellix Bio bags 2017 Fastest Growing Indian Company Excellence Award. The award will be presented during the National Seminar & Awards Ceremony on “Individual Achievements & National Development” at New Delhi.